Pancreatic Cancer Archives

Oncotarget News

Immunotherapy Success in KRAS G12C Adenosquamous Pancreatic Cancer

November 4, 2024

Here, we present a case of metastatic ASCP with a KRAS G12C mutation refractory to multiple lines of systemic therapy, including platinum-based chemotherapy and targeted inhibition of KRAS G12C.”BUFFALO,... read more

Oncotarget

Targeting ABC Transporters in PDAC – Past, Present, or Future?

July 10, 2024

it is crucial for the future application of ABC transporter inhibitors [...] to develop a stratification protocol [...] to identify those PDAC patients who are most likely to benefit from chemosensitization induced... read more

Figure 5: Effects of drugs on the levels of various proteins involved in DNA repair/DNA damage response.

Oncotarget

Synergistic Cytotoxicity of HDAC and PARP Inhibitors and Decitabine in Pancreatic Cancer Cells: Implications for Novel Therapy

June 5, 2024

The results provide novel preclinical data that demonstrate synergism between HDACi- and PARPi-mediated inhibition of DNA repair and decitabine in pancreatic cancer [...]”BUFFALO, NY- June 5, 2024 – A new research... read more

Figure 4: Correlation matrix with numerous significant positive correlations.

Oncotarget

Genetic and Therapeutic Landscapes in Cohort of Pancreatic Adenocarcinomas Using NGS and Machine Learning

February 14, 2024

Our study was designed to build specific mutational and therapeutic landscapes of pancreatic cancer among the Russian population.”BUFFALO, NY- February 14, 2024 – A new research paper was published in... read more

Oncotarget

Behind the Study: HER3: A Vital Target in Cancer Treatment

October 12, 2023

Dr. Omkar Desai from the Department of Surgery at Case Western Reserve University and University Hospitals Cleveland Medical Center, describes a research perspective he co-authored with Dr. Rui Wang that... read more

Figure 1: (A) Sliced fresh tumor samples were cultured in 96-well plates and viability was measured with PrestoBlue daily for 5 days. X-axis is days, and Y-axis is proportion of viability. (B) Sliced fresh tumor samples were embedded with paraffin, and tissue sections were stained with hematoxylin and eosin (H&E), Masson trichrome, αSMA, CD34 and Ki-67 antibodies.

Oncotarget

Real-Time Live Tissue Sensitivity Assay for Pancreatic Adenocarcinoma

September 19, 2023

This approach may allow clinicians to select the most effective therapeutic agents with real time in patients with pancreatic adenocarcinoma.”BUFFALO, NY- September 19, 2023 – A new research paper was... read more

Oncotarget

HER3: Survival Pathway and Therapeutic Target in Metastatic Colorectal and Pancreatic Cancer

May 24, 2023

we discovered that the surrounding liver EC microenvironment plays a key role in activating HER3 and promoting cell survival in mCRC and mPDAC [...].”BUFFALO, NY- May 24, 2023 – A new... read more

Oncotarget

Behind the Study: Metformin and Rapamycin as Maintenance Therapy

December 13, 2021

Dr. Katherine Bever from Johns Hopkins University discusses a research paper she co-authored that was published by Oncotarget, “An exploratory study of metformin with or without rapamycin as maintenance therapy... read more

Frank Slack, professor in the department of pathology at Beth Israel Deaconess Medical Center at Harvard Medical School

Oncotarget

Behind the Study: miRNA-185 Emerges as Regulator of KRAS

April 19, 2021

Behind the Study is a series of transcribed videos from researchers elaborating on their recent oncology-focused studies published in Oncotarget. A new Behind the Study is released each Monday. Visit... read more

Prof. Malka Cohen-Armon and her team at Tel Aviv University's Sackler Faculty of Medicine

Oncotarget

Behind the Study: Phenanthrene and Human Pancreatic Cancer Cells

March 15, 2021

The Behind the Study series transcribes videos of researchers elaborating on their recent papers published in Oncotarget. Visit the Oncotarget YouTube channel for more... read more